The Hematological Malignancies Emerging Therapeutics market size is expected to grow from 13.6 billion by the end of 2024 to 47.8 billion by 2033, registering a revenue CAGR of 15.00% during the forecast period. The major Hematological Malignancies Emerging Therapeutics market growth factors are facilitating the demand for hematologic malignancy testing kits and services, leveraging...